Trial Profile

A Dose-Escalation and Dose Expansion Phase I Clinical Study of HQP1351 in Patients with Tyrosine Kinase Inhibitor (TKI)-Refractory Chronic Myeloid Leukemia

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Nov 2024 According to an Ascentage Pharma media release, data from this trial to be presented, at the 66th American Society of Hematology (ASH) Annual Meeting. The 66th ASH Annual Meeting will take place on Dec 7-10, 2024, local time, both online and in-person in San Diego, CA (United States).
15 May 2024 According to an Ascentage Pharma media release, the company announced that the results from this study has been selected for Poster Presentations and to be presented at the 2024 European Hematology Association Hybrid Congress (EHA 2024).
13 Dec 2022 Results of five-year follow-up on safety and efficacy of olverembatinib, presented at the 64th American Society of Hematology Annual Meeting and Exposition.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com